Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
1 Year : From Oct 2018 to Oct 2019
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that management will attend the following conference:
- Management will host investor meetings during the William Blair & Company 3rd Annual Late-Stage Therapeutics Conference in New York, NY from Thursday, April 4, 2019.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of people with dermatological and immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes two FDA-approved medicines, one late-stage investigational medicine, and a pipeline powered by a robust R&D engine exploring protein kinase regulation. Aclaris Therapeutics’ active development programs focus on areas where significant treatment gaps exist, such as common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate Strategy/Investor Relations484firstname.lastname@example.org
Media ContactSheila KennedyVice President, Corporate Communications484email@example.com